American Healthcare REIT, Inc.
AHR
$50.44
+2.17%
American Healthcare REIT, Inc. (AHR) is a healthcare-focused real estate investment trust that owns a diversified portfolio of clinical healthcare properties, including medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. The company operates through four reportable segments — integrated senior health campuses, outpatient medical, triple-net leased properties, and SHOP — with the majority of revenue generated from its Integrated Senior Health Campuses segment. As a relatively recent public-market entrant (listed February 2024), AHR has quickly scaled into a mid-cap REIT with a market capitalization of roughly $11.4 billion, distinguishing itself through a differentiated senior-housing-heavy asset mix that captures demographic tailwinds from an aging U.S. population. The current investor narrative centers on the company's rapid operational turnaround — highlighted by 16.4% NOI growth and a swing from net losses in 2024 to consistent profitability through 2026 — alongside a strong institutional buy-in from analysts and funds, though the stock's recent pullback and premium valuation have sparked debate about whether the recovery is fully priced in.…
AHR
American Healthcare REIT, Inc.
$50.44
Related headlines
Investment Opinion: Should I buy AHR Today?
Based on the synthesis of fundamental, valuation, and analyst data, AHR warrants a Hold rating with a bullish bias. The core thesis is that AHR's exceptional operational turnaround and demographic tailwinds are compelling, but the stock's premium valuation and recent price weakness suggest that much of the good news is already priced in. The analyst consensus is 'strong_buy' with an average target of $64.40, implying 26.9% upside, but the current price of $50.75 already reflects significant optimism. Investors already holding the stock may consider maintaining positions, while new investors might wait for a better entry point.
Supporting evidence for the Hold rating includes: 1) Revenue growth of 24.29% year-over-year in Q2 2026, far exceeding the low-single-digit growth of mature healthcare REITs; 2) Four consecutive quarters of positive net income, with Q2 2026 net income of $30.61 million; 3) Debt-to-equity reduced to 0.51 from 0.95 in Q3 2024, strengthening the balance sheet; 4) Free cash flow TTM of $261.84 million comfortably covers the dividend, despite a payout ratio of 234%; and 5) Analyst targets range from $55 to $74, with the average at $64.40, suggesting at least 8.4% upside even in the most conservative case. However, the EV/EBITDA of 26.10x is well above the sector average of 15-18x, and the forward PE of 51.26x implies the market expects earnings to double, leaving little margin for error.
The biggest risks that could invalidate the thesis are: 1) A deceleration in revenue growth below 15%, which would likely trigger multiple compression; 2) A deterioration in free cash flow that threatens the dividend; and 3) A broader market downturn that disproportionately affects high-multiple stocks. The rating would upgrade to Buy if the stock pulls back to the $45-47 range (implied forward PE of ~45x) or if revenue growth accelerates above 25% with margin expansion. It would downgrade to Sell if revenue growth falls below 10% or if free cash flow declines significantly. Relative to its history and peers, AHR appears overvalued on most metrics, but the premium is partially justified by its superior growth profile. The stock is fairly valued to slightly overvalued at current levels, warranting a Hold.
Sign up to view all
AHR 12-Month Price Forecast
AHR presents a compelling growth story with exceptional revenue growth and a successful turnaround to profitability, but the stock's premium valuation and recent price weakness suggest that much of the optimism is already priced in. The analyst consensus is overwhelmingly bullish, yet the high forward PE of 51.26x implies the market expects earnings to double, leaving little room for execution missteps. The low beta of 0.745 and demographic tailwinds provide some downside protection, but the high short interest and liquidity concerns add risk. I would upgrade to bullish if the stock pulls back to the $45-47 range or if revenue growth accelerates above 25% with margin expansion. I would downgrade to bearish if revenue growth falls below 15% or if free cash flow declines significantly, threatening the dividend.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on American Healthcare REIT, Inc.'s 12-month outlook, with a consensus price target around $64.40 and implied upside of +27.7% versus the current price.
Average Target
$64.40
0 analysts
Implied Upside
+27.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $74
Analyst target range
AHR enjoys robust analyst coverage with 15 analysts contributing to the consensus, and the sentiment is overwhelmingly bullish: the recommendation is "strong_buy" with a recommendation mean of 1.4 (where 1.0 is a strong buy and 5.0 is a sell). The average target price is $64.40, which implies approximately +26.9% upside from the current price of $50.75. This consensus target is notably above the stock's 52-week high of $58.70, suggesting analysts believe the recent pullback is temporary and that the stock will not only recover but exceed its prior peak. The bullish consensus is reinforced by the institutional ratings data, which shows a steady stream of reiterations at Buy/Overweight/Outperform ratings from major firms including Scotiabank, Barclays, KeyBanc, RBC Capital, Truist, Citigroup, Citizens, and UBS throughout mid-2026, with Citigroup notably upgrading from Neutral to Buy in June 2026.
The target price range spans from a low of $55.00 to a high of $74.00, a spread of $19.00 or approximately 34.5% of the average target — a moderately wide range that signals some uncertainty about the pace of the recovery. The low target of $55.00 still implies +8.4% upside from the current price, suggesting that even the most conservative analyst sees the stock as undervalued at current levels, likely pricing in modest growth and stable margins. The high target of $74.00 implies +45.8% upside and would require significant multiple expansion and/or accelerating NOI growth, potentially driven by continued occupancy gains in the senior housing portfolio, accretive acquisitions, or a re-rating as the company establishes a longer public track record. The tight clustering of recent ratings at Buy/Overweight with no downgrades in the visible data, combined with the strong_buy consensus, indicates high conviction among analysts that AHR's operational momentum will continue to drive shareholder value.
Bulls vs Bears: AHR Investment Factors
The bull case for AHR rests on its exceptional 24.29% revenue growth, successful turnaround to profitability, and strong analyst support, while the bear case centers on extreme valuation multiples and recent price weakness. Currently, the bull evidence appears stronger due to the company's operational momentum and demographic tailwinds, but the premium valuation and high short interest introduce significant risk. The single most important tension is whether AHR can sustain its rapid growth to justify its elevated multiples; if growth decelerates, the stock could face a sharp re-rating. Conversely, continued execution could drive the stock toward analyst targets. Investors must weigh the potential for further upside against the risk of multiple compression.
Bullish
- Explosive revenue growth: Q2 2026 revenue of $674.25 million grew 24.29% year-over-year, with sequential increases every quarter since Q1 2025. This pace is exceptional for a healthcare REIT and reflects strong occupancy and rate growth in the Integrated Senior Health Campuses segment.
- Turnaround to sustained profitability: Net income turned positive in Q3 2025 and has remained positive for four consecutive quarters, reaching $30.61 million in Q2 2026. This marks a decisive inflection from the -$31.77 million loss in Q4 2024.
- Strong analyst consensus and upside: 15 analysts rate the stock a 'strong_buy' with a mean recommendation of 1.4 and an average target price of $64.40, implying 26.9% upside from the current $50.75. The low target of $55.00 still suggests 8.4% upside.
- Deleveraging balance sheet: Debt-to-equity has fallen to 0.51 from 0.83 in Q4 2024 and 0.95 in Q3 2024, reflecting deliberate debt reduction and equity issuance. This improves financial flexibility and reduces interest rate sensitivity.
Bearish
- Extreme valuation multiples: The trailing PE is 112.05x and forward PE is 51.26x, while EV/EBITDA is 26.10x—well above the healthcare REIT sector average of 15-18x. The PS ratio of 3.46x also exceeds the typical 2-4x range, leaving little room for error.
- Recent price weakness and underperformance: The stock has declined 9.71% over the past month and 7.79% over three months, significantly underperforming SPY. Relative strength versus SPY is -10.30 over one month and -11.13 over three months, indicating a stock-specific de-rating.
- Dividend not covered by earnings: The payout ratio is 234%, meaning the dividend is not covered by net income. While free cash flow of $261.84 million TTM covers the $47.61 million quarterly dividend, the high payout ratio signals limited flexibility if cash flow deteriorates.
- Liquidity concerns: The current ratio of 0.37 is well below 1.0, indicating potential near-term liquidity tightness. Although common for REITs with predictable cash flows, it poses a risk if refinancing conditions tighten.
AHR Technical Analysis
AHR is in a sustained, albeit choppy, uptrend over the trailing year, with a 1-year price change of +22.82% versus SPY's +15.01%, delivering 7.81 percentage points of relative outperformance. At a current price of $50.75, the stock sits at approximately 57.6% of its 52-week range (low of $40.00, high of $58.70), meaning it is in the upper-middle portion of its band but well off its highs — a positioning that suggests neither extreme momentum nor deep-value territory, but rather a consolidation phase within a broader advance. The stock's 6-month gain of +5.53% and YTD gain of +7.43% confirm the longer-term constructive trend remains intact despite near-term softness.
Short-term momentum has clearly decelerated and diverged from the longer-term trend: the 1-month change is -9.71% and the 3-month change is -7.79%, both sharply negative against a positive 1-year return. This divergence is corroborated by relative strength metrics — AHR's 1-month relative strength versus SPY is -10.30 and its 3-month relative strength is -11.13, indicating significant underperformance over the recent quarter even as the 1-year relative strength remains positive at +7.81. The magnitude of the 1-month decline (-9.71%) against a modest SPY gain of +0.59% suggests this is a stock-specific de-rating rather than a market-driven pullback, potentially reflecting profit-taking after the strong run or concerns about valuation. With a beta of 0.745, AHR is roughly 25% less volatile than the broad market, which somewhat cushions the downside but also means the recent sell-off is notable for a low-beta name.
Key technical levels are well-defined: the 52-week low at $40.00 serves as the major support zone, while the 52-week high at $58.70 represents the primary resistance ceiling. A breakout above $58.70 would signal renewed momentum and likely confirm the resumption of the primary uptrend, potentially opening the door to the analyst high target of $74.00; conversely, a breakdown below $40.00 would represent a significant technical failure and could trigger a deeper correction. The maximum drawdown of -14.08% over the period reflects moderate risk, and with a short ratio of 9.69 — indicating nearly 10 days of average volume needed to cover short positions — there is meaningful bearish positioning that could fuel a short squeeze on any positive catalyst. The current price of $50.75 is roughly 27% above the 52-week low and about 13.5% below the 52-week high, placing the stock in a neutral-to-slightly-favorable risk/reward zone within its established range.
Beta
0.80
0.80x market volatility
Max Drawdown
-14.5%
Largest decline past year
52-Week Range
$40-$59
Price range past year
Annual Return
+25.5%
Cumulative gain past year
| Period | AHR Return | S&P 500 |
|---|---|---|
| 1m | -7.6% | +1.0% |
| 3m | -5.8% | +2.5% |
| 6m | +2.5% | +13.9% |
| 1y | +25.5% | +15.0% |
| ytd | +6.8% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AHR Fundamental Analysis
AHR's revenue trajectory is clearly accelerating: Q2 2026 revenue reached $674.25 million, representing 24.29% year-over-year growth versus Q2 2025's $542.50 million. The multi-quarter trend is consistently upward — from $540.60 million in Q1 2025 to $572.94 million in Q3 2025, $604.08 million in Q4 2025, $650.77 million in Q1 2026, and $674.25 million in Q2 2026 — demonstrating sequential growth in every quarter. The dominant revenue driver is the Resident Fees and Services line at $634.52 million, which reflects the Integrated Senior Health Campuses segment's strong occupancy and rate growth, and this segment's momentum is the primary engine behind the company's overall top-line acceleration. The 24.29% YoY growth rate is exceptional for a healthcare REIT and suggests the company is capturing significant demographic demand, though investors should monitor whether this pace is sustainable as the base of comparison grows.
Profitability has inflected decisively positive: Q2 2026 net income was $30.61 million (net margin of 4.54%), a dramatic improvement from the -$6.80 million loss in Q1 2025 and the -$31.77 million loss in Q4 2024. However, the gross margin picture is distorted — Q2 2026 reported a gross margin of -1.04% (gross profit of -$7.01 million), which appears anomalous versus the more typical ~20-21% gross margins reported in prior quarters (Q1 2026: 21.30%, Q4 2025: 20.49%, Q3 2025: 20.67%), likely due to a one-time accounting adjustment or reclassification in cost of revenue. Operating margin stands at 7.47% and EBITDA was $121.73 million in Q2 2026 with an EBITDA ratio of 18.05%, showing healthy cash-generating capacity. The company has now posted positive net income for four consecutive quarters (Q3 2025 through Q2 2026), a critical milestone that validates the turnaround thesis and supports the premium multiple.
Balance sheet and cash flow metrics present a mixed but improving picture: debt-to-equity is 0.51, down substantially from 0.83 in Q4 2024 and 0.95 in Q3 2024, reflecting deliberate deleveraging and equity issuance. However, the current ratio of 0.37 is well below 1.0, indicating potential near-term liquidity tightness, though this is common for REITs with predictable rental cash flows. Free cash flow TTM is $261.84 million, and Q2 2026 free cash flow was $70.93 million, comfortably covering the $47.61 million in dividends paid during the quarter. ROE is low at 2.10% and ROA at 2.10%, which is modest even for a REIT but reflects the early stage of the earnings recovery. The company issued $227.08 million in common stock in Q2 2026 and $671.38 million in Q4 2025, using capital markets to fund acquisitions and deleverage — a strategy that reduces financial risk but dilutes existing shareholders. With a dividend yield of 2.09% and a payout ratio of 234%, the dividend is not currently covered by net income but is covered by free cash flow, which is the more relevant metric for REIT sustainability.
Quarterly Revenue
$674250000.0B
2026-06
Revenue YoY Growth
+24.3%
YoY Comparison
Gross Margin
-1.0%
Latest Quarter
Free Cash Flow
$261842000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AHR Overvalued?
Because AHR reported positive trailing net income ($30.61 million in Q2 2026), the PE ratio is the appropriate primary metric, though it must be interpreted with caution given the company's recent emergence from losses. The trailing PE is 112.05x, while the forward PE is 51.26x — a dramatic gap that implies the market expects earnings to roughly double over the next year, consistent with the rapid NOI growth and occupancy gains underway. The PEG ratio of -0.46 is not meaningful given the negative earnings history, and the PS ratio of 3.46x and EV/EBITDA of 26.10x provide additional context: the EV/EBITDA multiple is elevated for a healthcare REIT, suggesting the market is pricing in substantial future EBITDA growth.
Relative to the broader REIT sector, AHR trades at a significant premium: the PS ratio of 3.46x compares to a typical healthcare REIT range of 2-4x, while the EV/EBITDA of 26.10x is well above the sector average of roughly 15-18x. The PB ratio of 2.35x is also above the sector median of approximately 1.5-2.0x. This premium is partially justified by AHR's superior growth profile — 24.29% YoY revenue growth and 16.4% NOI growth far exceed the low-single-digit growth typical of mature healthcare REITs — but the magnitude of the premium leaves little room for execution missteps. The dividend yield of 2.09% is below the sector average of 3-4%, reflecting the stock's appreciation and the company's decision to retain capital for growth rather than maximize current income.
Historically, AHR's valuation has expanded dramatically: the PE ratio has ranged from negative territory in 2023-2024 to 31.83x in Q3 2025, 193.82x in Q4 2025, 90.69x in Q1 2026, and 81.48x in Q2 2026, while the PS ratio has climbed from 1.81x in Q4 2023 to 14.70x in Q2 2026 (though the current reported PS of 3.46x reflects a different share count basis). The PB ratio has risen from 0.69x in Q4 2023 to 2.35x currently, a 3.4x expansion that reflects both the operational turnaround and the market's willingness to pay up for the story. The current valuation sits near the high end of the company's historical band, implying that the market is pricing in optimistic expectations for continued growth — a value opportunity only if the company can sustain its current trajectory, but a risk if growth decelerates.
PE
112.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 32x~243x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for AHR are significant. The company's current ratio of 0.37 is well below 1.0, indicating potential near-term liquidity tightness, though this is common for REITs with predictable rental income. The payout ratio of 234% means the dividend is not covered by net income, and while free cash flow of $261.84 million TTM covers the $47.61 million quarterly dividend, any decline in cash flow could jeopardize the dividend. Additionally, the gross margin in Q2 2026 was -1.04%, a sharp anomaly versus the typical ~20-21% range, likely due to a one-time accounting adjustment, but it highlights potential earnings volatility. The company's reliance on the Integrated Senior Health Campuses segment for the majority of revenue also concentrates risk; any downturn in senior housing demand or occupancy could disproportionately impact results.
Market and competitive risks are also pronounced. AHR trades at a significant premium to its sector, with an EV/EBITDA of 26.10x versus the sector average of 15-18x, and a PS ratio of 3.46x compared to the typical 2-4x range. This premium leaves little room for execution missteps and increases the risk of multiple compression if growth slows. The stock's beta of 0.745 indicates lower volatility than the market, but its recent 9.71% one-month decline amid a modest SPY gain of 0.59% suggests a stock-specific de-rating, possibly due to profit-taking or valuation concerns. Competitive pressures in healthcare real estate, including from other REITs and private operators, could limit AHR's ability to maintain occupancy and rate growth. Regulatory changes in healthcare reimbursement or senior housing regulations could also pose headwinds.
The worst-case scenario for AHR would involve a combination of slowing revenue growth, margin compression, and a broader market downturn. If revenue growth decelerates from 24.29% to single digits, the premium valuation could contract sharply, pushing the stock toward its 52-week low of $40.00, which represents a 21.2% decline from the current price of $50.75. The analyst low target of $55.00 is above the current price, but in a severe bear case, the stock could test $40.00 or lower, especially if short interest (short ratio of 9.69) fuels a sell-off. A breakdown below $40.00 would represent a significant technical failure and could trigger a deeper correction, potentially to the $35-38 range, implying a loss of 25-30% from current levels. Investors should be prepared for such downside risk given the stock's high valuation and recent negative momentum.
FAQ
The key risks of holding AHR include: 1) Valuation risk—the stock trades at a premium (forward PE of 51.26x, EV/EBITDA of 26.10x), leaving little room for error; 2) Liquidity risk—the current ratio of 0.37 is well below 1.0, indicating potential near-term liquidity tightness; 3) Dividend risk—the payout ratio of 234% means the dividend is not covered by net income, and while free cash flow covers it, any decline could threaten the payout; 4) Growth deceleration risk—revenue growth of 24.29% may not be sustainable, and a slowdown could trigger a de-rating; and 5) Short interest risk—the short ratio of 9.69 reflects meaningful bearish sentiment that could amplify downside moves. These risks are ranked from highest to lowest severity, with valuation and growth deceleration being the most critical.
Our 12-month forecast for AHR includes three scenarios: Bull case (25% probability) with a target range of $64.40-$74.00, assuming sustained 24%+ revenue growth and multiple expansion; Base case (55% probability) with a target range of $55.00-$64.40, assuming moderating growth of 15-20% and stable margins; and Bear case (20% probability) with a target range of $40.00-$55.00, assuming growth decelerates below 10% and multiple compression. The base case is most likely, aligning with the analyst average target of $64.40, which implies 26.9% upside. The key assumption behind the base case is that AHR maintains solid operational execution without significant margin erosion. However, the wide range of outcomes reflects uncertainty around the sustainability of growth and the premium valuation.
AHR appears overvalued relative to its peers and historical averages. The trailing PE of 112.05x and forward PE of 51.26x are significantly higher than the broader REIT sector, while the EV/EBITDA of 26.10x exceeds the typical 15-18x range for healthcare REITs. The PS ratio of 3.46x is also above the sector norm of 2-4x. However, this premium is partially justified by AHR's superior growth profile—24.29% revenue growth versus low-single-digit growth for mature REITs. The market is pricing in expectations for continued rapid growth and margin expansion, as evidenced by the forward PE implying earnings to double. If AHR fails to meet these expectations, the stock could face significant multiple compression. Therefore, while not egregiously overvalued given its growth, the stock is not undervalued and offers limited margin of safety.
AHR is a good buy for growth-oriented investors with a long-term horizon, but the current valuation warrants caution. The stock trades at a forward PE of 51.26x and EV/EBITDA of 26.10x, well above sector averages, implying that much of the growth is already priced in. Analyst consensus is 'strong_buy' with an average target of $64.40, suggesting 26.9% upside, but the recent 9.71% one-month decline and high short interest (short ratio of 9.69) indicate near-term risks. The company's 24.29% revenue growth and four consecutive quarters of profitability are impressive, but investors should consider waiting for a pullback to the $45-47 range for a better risk/reward. For those with a high risk tolerance and a 2-3 year horizon, AHR could be a rewarding investment, but it is not a low-risk entry at current levels.
AHR is more suitable for long-term investment (2-3 years or more) than short-term trading. The company is in a growth phase, with revenue expanding at 24.29% year-over-year and a turnaround to profitability that is still early in its trajectory. The low beta of 0.745 suggests lower volatility than the market, but the stock has experienced a 9.71% one-month decline, indicating short-term price swings can be significant. The dividend yield of 2.09% is modest and the payout ratio of 234% means income is not a primary attraction. Earnings visibility is improving but still limited given the recent IPO in February 2024. For short-term traders, the high short interest (short ratio of 9.69) could create volatility, but the lack of a clear near-term catalyst makes timing difficult. A minimum holding period of 2-3 years is recommended to allow the growth story to unfold and for the company to establish a longer track record.